Dr. Lal Path Labs Ltd.
NSE: LALPATHLABDr. Lal Path Labs Ltd.: A 30-second snapshot
Dr. Lal PathLabs trades at 1878.8, up 25.37% over the past year and 22.88% over three months, sitting 2.14% below its 52-week high with an RSI of 73.22 (overbought). Q1 FY27 headlines from late July 2026 describe 19.1% revenue growth and a 31% EBITDA margin, consistent with 5-year revenue and earnings CAGRs of 19.1% and 27.8% respectively. The stock trades at a trailing PE of 58.95x (43.97x forward) against Pharma peers ranging 28.9x-74.6x, carries debt-to-equity of roughly 0.08x, and shows a persistence consistency score of 85.
P/E
58.9
Forward P/E
44.0
ROE
—
Debt / Equity
7.83
Profit Margin
+18.8%
Div. Yield
+1.1%
5Y ROE > 15%
3/5
5Y FCF > 0
4/5
Quality
73/100
News
8 headlines · 5 positive · 0 negative
LALPATHLAB: Q1 FY27 delivered 19.1% revenue growth and 31% EBITDA margin, with strong volume and innovation - TradingView
TradingView
LALPATHLAB: Q1 FY27 delivered robust double-digit revenue and profit growth, with strong operational momentum - TradingView
TradingView
Dr. Lal PathLabs Limited Declares Interim Dividend for the Fiscal Year 2026-2027 - marketscreener.com
marketscreener.com
LALPATHLAB: Record quarterly revenue growth and margin expansion driven by strong volume gains - TradingView
TradingView
LALPATHLAB: Revenue and profit rose year-over-year, with new acquisitions and a dividend declared - TradingView
TradingView
Recent context
- ·Headlines from late July 2026 (TradingView, marketscreener.com) describe Q1 FY27 revenue growth of 19.1%, record quarterly revenue, and margin expansion driven by volume gains.
- ·An interim dividend for FY2026-27 was declared per a July 24, 2026 announcement; dividend yield stands at 1.06%.
- ·News sentiment across the 8 tracked headlines is positive (5 positive, 3 neutral, 0 negative), coinciding with the stock's 25.37% one-year and 22.88% three-month price gains.
Strengths
- +5-year earnings CAGR of 27.8% has outpaced 5-year revenue CAGR of 19.1%, aligned with an 18.75% profit margin and Q1 FY27 headlines citing a 31% EBITDA margin.
- +Debt-to-equity is low at roughly 0.08x (Yahoo-scaled value of 7.83 divided by 100), and the persistence data flags the debt trend as falling.
- +Quality score of 57 ranks 1st of 6 within its tracked Pharma peer set (APOLLOHOSP 44, SUNPHARMA 56, MAXHEALTH 37, CIPLA 28, DRREDDY 4).
- +FCF was positive in 4 of the years tracked and the consistency score stands at 85; mean analyst rating is 1.81 across 26 analysts (1-5 scale, lower = more constructive).
Weaknesses
- −Trailing PE of 58.95x (43.97x forward) ranks 4th of 6 among tracked Pharma peers, above CIPLA (35.4x), DRREDDY (28.9x) and SUNPHARMA (41.6x) though below APOLLOHOSP (66.4x) and MAXHEALTH (74.6x).
- −RSI of 73.22 is in overbought territory; price is 13.4% above the 50-DMA and 25.0% above the 200-DMA following a 22.88% three-month rally, with the stock 2.14% below its 52-week high.
- −Current-period ROE is reported as null in the fundamental snapshot even though profit margin and persistence metrics are populated, and ROE exceeded 15% in only 3 of the years tracked in the persistence window.
- −No resistance levels were identified in the technical scan, consistent with the stock trading near its 52-week high with limited historical overhead supply to reference.
Open questions
- ?Does the 31% EBITDA margin cited in Q1 FY27 commentary reflect a durable structural shift or a transient volume/mix benefit that could normalize in later quarters?
- ?How does the current RSI of 73.22 and 25% extension above the 200-DMA compare with the stock's own history of overbought readings and what followed them previously?
- ?What would need to be true of forward earnings for the 43.97x forward PE to converge toward the peer range of 28.9x-41.6x seen at CIPLA, DRREDDY and SUNPHARMA?
- ?What acquisitions or capacity additions referenced in recent headlines are driving revenue growth, and how are they being funded given the reported debt-to-equity trend?
Peer comparison: Pharma
Ranks 1 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| LALPATHLAB | Dr. Lal Path Labs Ltd.You're viewing | 58.9 | — | 57 |
| Industry avg | across 5 peers | 49.4 | +14.8% | 34 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.6 | +14.7% | 56 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 66.4 | +21.5% | 44 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 74.6 | +14.3% | 37 |
| CIPLA | Cipla Ltd. | 35.4 | — | 28 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 28.9 | +8.8% | 4 |
Technical state
Current price
₹1,878.80
SMA 50
₹1,656.35
SMA 200
₹1,503.27
RSI (14)
73.2 (overbought)
From 52w high
-2.1%
1Y return
+25.4%
3M return
+22.9%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Risk flags
- mediumTrailing PE of 58.95x (43.97x forward) ranks 4th of 6 within its tracked Pharma peer set, above CIPLA (35.4x), DRREDDY (28.9x) and SUNPHARMA (41.6x) though below APOLLOHOSP (66.4x) and MAXHEALTH (74.6x); the gap between trailing and forward PE implies the market is pricing in a step-up in near-term earnings.
- mediumRSI of 73.22 is in overbought territory; current price of 1878.8 is 13.4% above the 50-DMA (1656.35) and 25.0% above the 200-DMA (1503.27) after a 22.88% three-month rally, with the stock only 2.14% below its 52-week high.
- lowCurrent-period ROE is reported as null in the fundamental snapshot even though profit margin (18.75%) and persistence metrics (consistency score 85) are populated; the persistence data separately shows ROE exceeded 15% in only 3 of the years tracked.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 11 Aug 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 31 Jul 2026 · rotates through NIFTY 500 every ~5 days